Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
6990.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$103.68B
Close$
Share Statistics
| Market cap | $103.68 Billion |
|---|---|
| Enterprise Value | $100.99 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.66 |
| Beta | -0.03 |
| Outstanding Shares | 233,275,416 |
Return
| Return on Equity | 2.38% |
|---|---|
| Return on Assets | 2.01% |
| Return on Invested Capital | -0.50% |
Valuation & Multiples
| P/E Ratio | 688.16 |
|---|---|
| PEG | -124.93 |
| Price to Sales | 48.58 |
| Price to Book Ratio | 19.87 |
| Enterprise Value to Revenue | 45.91 |
| Enterprise Value to EBIT | -3730.3 |
| Enterprise Value to Net Income | 796 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$1.45 B
Average shareholder expectationNext Earnings Call
Expected Date
March 29, 2027
EPS Estimate
$0.46
Average shareholder expectationRevenue Estimate
$1.60 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2,300 employees
CEO: Jun You Ge Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas...